Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.

Cancer discovery - 1 Jan 2014

Shi Hubing, Hong Aayoung, Kong Xiangju, Koya Richard C, Song Chunying, Moriceau Gatien, Hugo Willy, Yu Clarissa C, Ng Charles, Chodon Thinle, Scolyer Richard A, Kefford Richard F, Ribas Antoni, Long Georgina V, Lo Roger S

Abstract excerpt

BRAF inhibitor (BRAFi) therapy leads to remarkable anti melanoma responses, but the initial tumor shrinkage is commonly incomplete, providing a nidus for subsequent disease progression. Adaptive signaling may underlie early BRAFi resistance and influence the selection pattern for genetic variants, causing late, acquired resistance. We show here that BRAFi (or BRAFi + MEKi) therapy in patients frequently led to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to HEK293 Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins c-akt

Share to Receptor, Platelet-Derived Growth Factor beta

Share to Skin Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 24265152
DOI: 10.1158/2159-8290.CD-13-0279
PMCID: PMC3893054

Genes

AKT1
BRAF
PTEN

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.PMID 24265152Read ↗

AXL/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma.Semantic proximity Read ↗

BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma modelSemantic proximity Read ↗

PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas.Semantic proximity Read ↗

Towards a unified model of RAF inhibitor resistance.Semantic proximity Read ↗

PERK mediates resistance to BRAF inhibition in melanoma with impaired PTENSemantic proximity Read ↗

BRAFV600E negatively regulates the AKT pathway in melanoma cell lines.Semantic proximity Read ↗

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.Semantic proximity Read ↗

Adaptive resistance to <scp>RAF</scp> inhibitors in melanomaSemantic proximity Read ↗

Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma.Semantic proximity Read ↗

Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition.Semantic proximity Read ↗

AKT2 Loss Impairs BRAF-Mutant Melanoma MetastasisSemantic proximity Read ↗

P21‐activated kinase 1 regulates resistance to BRAF inhibition in human cancer cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.